Allakos (ALLK) Stock Forecast, Price & News

Allakos (NASDAQ:ALLK) Frequently Asked Questions

Is Allakos a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Allakos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View analyst ratings for Allakos or view top-rated stocks.

When is Allakos' next earnings date?

Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Allakos.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) issued its quarterly earnings results on Friday, May, 6th. The company reported ($3.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by $1.65.
View Allakos' earnings history.

What price target have analysts set for ALLK?

10 brokers have issued 12 month target prices for Allakos' stock. Their forecasts range from $13.00 to $155.00. On average, they anticipate Allakos' stock price to reach $68.42 in the next twelve months. This suggests a possible upside of 2,251.3% from the stock's current price.
View analysts' price targets for Allakos or view top-rated stocks among Wall Street analysts.

Who are Allakos' key executives?

Allakos' management team includes the following people:

• Dr. Robert Alexander Ph.D., CEO & Director (Age 52, Pay $1.39M)
• Dr. Adam L. Tomasi Ph.D., Pres & COO (Age 52, Pay $1.06M)
• Mr. Baird Radford III, Chief Financial Officer
• Mr. Mark Asbury J.D., Exec. Officer (Age 59, Pay $701.69k)
• Dr. Ruby Casareno Ph.D., Sr. VP of Technical Operations
• Meg Fitzgerald, Sr. VP, Gen. Counsel, Sec. and Chief Compliance Officer
• Dr. Sally D. Bolmer, Sr. VP of Regulatory Affairs & Drug Devel.
• Dr. Henrik Sandvad Rasmussen, Strategic Advisor (Age 63)
• Dr. Craig Paterson M.D., Chief Medical Officer
• Brad Youngblood, Head of Research

Who are some of Allakos' key competitors?

Some companies that are related to Allakos include Relmada Therapeutics (RLMD), Atai Life Sciences (ATAI), Rocket Pharmaceuticals (RCKT), PMV Pharmaceuticals (PMVP), PureTech Health (PRTC), uniQure (QURE), SIGA Technologies (SIGA), Design Therapeutics (DSGN), Zealand Pharma A/S (ZEAL), Atea Pharmaceuticals (AVIR), Eagle Pharmaceuticals (EGRX), AnaptysBio (ANAB), Gossamer Bio (GOSS), Amarin (AMRN) and Kiniksa Pharmaceuticals (KNSA).
View all of ALLK's competitors.

What other stocks do shareholders of Allakos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS).

When did Allakos IPO?

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.32%), Vanguard Group Inc. (4.84%), Goldman Sachs Group Inc. (1.84%), State Street Corp (1.43%), PDT Partners LLC (1.21%) and Clearline Capital LP (0.98%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends for Allakos.

Which major investors are selling Allakos stock?

ALLK stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Simplex Trading LLC, Group One Trading L.P., Citigroup Inc., RBF Capital LLC, Cutler Group LP, and Engineers Gate Manager LP. Company insiders that have sold Allakos company stock in the last year include Adam Tomasi, Henrik S Md Rasmussen, Robert Alexander, and Steven P James.
View insider buying and selling activity for Allakos or view top insider-selling stocks.

Which major investors are buying Allakos stock?

ALLK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., PDT Partners LLC, Clearline Capital LP, JPMorgan Chase & Co., Acadian Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, BlackRock Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Allakos or or view top insider-buying stocks.

How do I buy shares of Allakos?

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $2.91.

How much money does Allakos make?

Allakos has a market capitalization of $159.41 million. The company earns $-269.86 million in net income (profit) each year or ($7.56) on an earnings per share basis.

How many employees does Allakos have?

Allakos employs 192 workers across the globe.

What is Allakos' official website?

The official website for Allakos is www.allakos.com.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at (650) 597-5002 or via email at [email protected].